Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TYK MedicinesHKSE:02410 -4.08%7 Current Ratio is 1.43 as of Dec. 2025, which is 66% above its 10-year median of 0.86. GuruFocus rates HKSE:02410 with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, TYK Medicines ranks worse than 76.47% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. TYK Medicines's current ratio for the quarter that ended in Dec. 2025 was 1.43.
TYK Medicines has a current ratio of 1.43. It generally indicates good short-term financial strength.
The historical rank and industry rank for TYK Medicines's Current Ratio or its related term are showing as below:
HKSE:02410'
s Current Ratio Range Over the Past 10 Years
Min: 0.18 Med: 0.86 Max: 1.97
Current: 1.43
During the past 4 years, TYK Medicines's highest Current Ratio was 1.97. The lowest was 0.18. And the median was 0.86.
HKSE:02410's Current Ratio is ranked worse than 76.47% of 1411
companies
in the Biotechnology industry
Industry Median: 3.85
vs HKSE:02410: 1.43
TYK Medicines (HKSE:02410) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
TYK Medicines Current Ratio Related Terms
TYK Medicines Current Ratio Historical Data
* Premium members only.
The historical data trend for TYK Medicines's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02410 vs VRTX, REGN, RVMD: Current Ratio Comparison
For the Biotechnology subindustry, TYK Medicines's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TYK Medicines Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TYK Medicines's Current Ratio distribution charts can be found below:
* The bar in red indicates where TYK Medicines's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYK Medicines (HKSE:02410) has a Current Ratio of 1.43 as of Dec. 2025. This is 66% above median its historical median of 0.86. Over the past decade, TYK Medicines' Current Ratio has ranged from 0.18 to 1.97. According to the industry distribution chart, TYK Medicines ranks #1079 out of 1411 companies in the Biotechnology industry, placing it in the top 76.5%.
Is TYK Medicines' Current Ratio too high?
TYK Medicines' current Current Ratio of 1.43 is 66% above median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.18 to a high of 1.97. The Biotechnology industry median Current Ratio is 3.85. TYK Medicines' value of 1.43 is 62.9% below this industry median. Based on the distribution chart, TYK Medicines ranks #1079 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TYK Medicines has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TYK Medicines' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TYK Medicines ranks #1079 out of 1411 companies for Current Ratio. This places TYK Medicines in the lower half of its industry. The industry median Current Ratio is 3.85. TYK Medicines' value of 1.43 is 62.9% below this benchmark. Historically, TYK Medicines' own Current Ratio has ranged from 0.18 to 1.97 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 3.85, TYK Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.85, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TYK Medicines's current Current Ratio of 1.43 is 62.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TYK Medicines's current Current Ratio is 1.43, which is 66% above median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TYK Medicines stock overvalued right now?
TYK Medicines (HKSE:02410) has a current Current Ratio of 1.43. The current Current Ratio is 1.43, which is 66% above median its 10-year median of 0.86 and 62.9% below the Biotechnology industry median of 3.85. TYK Medicines' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For TYK Medicines (HKSE:02410), the current Current Ratio is 1.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with10 drug candidates, including Core Product TY-9591, five clinical stage products, and four preclinical stage or early clinical development stage.
7GF Score
Get the complete analysis for HKSE:02410
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02410 has been successfully added to your 
